Laboratoire Synthèse et Réactivité des Substances Naturelles, Université de Poitiers, CNRS-UMR 6514, 40 Avenue du Recteur Pineau, Poitiers, F-86022, France.
Eur J Med Chem. 2010 Jun;45(6):2095-116. doi: 10.1016/j.ejmech.2010.02.030. Epub 2010 Feb 14.
Histone deacetylase inhibitors are a large group of diverse molecules intrinsically able to inhibit cell proliferation in various cancer cell lines. Their apoptotic effects have been linked to the modulation in the expression of several regulatory tumor suppressor genes caused by the modified status of histone acetylation, a key event in chromatin remodelling. As the initial histone deacetylase activity of HDAC has been extended to other proteins, the possible other biological mechanisms modified by HDAC inhibitor treatments are still to be clarified. The need for HDAC isoform selective inhibitors is an important issue to serve this goal. This review discusses the approaches proposed by several research groups working on the synthesis of HDAC inhibitors, based on modelling studies and the way these findings were used to obtain new HDAC inhibitors with possible isoform selectivity.
组蛋白去乙酰化酶抑制剂是一大类具有内在能力的多样化分子,能够抑制各种癌细胞系的细胞增殖。它们的凋亡作用与几种调节肿瘤抑制基因的表达有关,这些基因的表达受到组蛋白乙酰化状态的调节,组蛋白乙酰化是染色质重塑的关键事件。随着 HDAC 的初始组蛋白去乙酰化酶活性扩展到其他蛋白质,HDAC 抑制剂治疗可能改变的其他生物学机制仍有待阐明。需要 HDAC 同工型选择性抑制剂是实现这一目标的重要问题。本文综述了几个研究小组在基于建模研究和这些发现如何用于获得可能具有同工型选择性的新型 HDAC 抑制剂的基础上,提出的合成 HDAC 抑制剂的方法。